References of "Servais, Sophie"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCircadian and circannual variations in cord blood hematopoietic cell composition
Servais, Sophie ULg; BAUDOUX, Etienne ULg; Brichard, B. et al

in Haematologica (in press)

Detailed reference viewed: 6 (2 ULg)
Full Text
Peer Reviewed
See detailLong term Immune Reconstitution and infection burden after Mismatched Hematopoietic Stem Cell Transplantation
SERVAIS, Sophie ULg; Lengline, Etienne; Porcher, Raphael et al

in Biology of Blood & Marrow Transplantation (2014), 20(4), 507-517

Mismatched unrelated donor (MMUD) or umbilical cord blood (UCB) can be chosen as alternative donors for allogeneic stem cell transplantation but might be associated with long lasting immune deficiency ... [more ▼]

Mismatched unrelated donor (MMUD) or umbilical cord blood (UCB) can be chosen as alternative donors for allogeneic stem cell transplantation but might be associated with long lasting immune deficiency. Sixty-six patients who underwent a first transplantation from either UCB or 9/10 MMUD (n= 36) and who survived beyond 3 months were evaluated. Immune reconstitution was prospectively assessed at sequential time points after transplantation. NK, B, CD4+ and CD8+T cells and their subsets as well as regulatory T cells (Treg) were studied. Detailed analyses on infections occurring after 3 months were also assessed. The 18-month cumulative incidences of infection-related death were 8 and 3%, and of infections were 72 and 57% after MMUD and UCB transplantation, respectively. Rates of infection per 12 patient-month were roughly 2 overall (1 for bacterial, 0.9 for viral and 0.3 for fungal infections). Memory, naïve CD4+ and CD8+T cells, naïve B cells and Treg cells reconstitution between the 2 sources was roughly similar. Absolute CD4+T cells hardly reached 500 per μL by one year posttransplantation and most B cells were of naïve phenotype. Correlations between immune reconstitution and infection were then performed by multivariate analyses. Low CD4+ and high CD8+T cells absolute counts at 3 months were linked to increased risks of overall and viral (but not bacterial) infections. When assessing for the naïve/memory phenotypes at 3 months among the CD4+ T cell compartment, higher percentages of memory subsets were protective against late infections: central memory CD4+T cells protected against overall and bacterial infections; late effector memory CD4+T cells protected against overall, bacterial and viral infections. At the opposite, high percentage of effector- and late effector-memory subsets at 3 months among the CD8+ T cell compartment predicted higher risks for viral infections. Patients transplanted from alternative donors represent a population with very high risk of infection. Detailed phenotypic analysis of immune reconstitution may help to evaluate infection risk and to adjust infection prophylaxis. [less ▲]

Detailed reference viewed: 23 (6 ULg)
Full Text
Peer Reviewed
See detailLong term Immune Reconstitution and infection burden after Mismatched Hematopoietic Stem Cell Transplantation
SERVAIS, Sophie ULg; Lengline, Etienne; Porcher, Raphael et al

in Biology of Blood & Marrow Transplantation (2014), 20(4), 507-517

Mismatched unrelated donor (MMUD) or umbilical cord blood (UCB) can be chosen as alternative donors for allogeneic stem cell transplantation but might be associated with long lasting immune deficiency ... [more ▼]

Mismatched unrelated donor (MMUD) or umbilical cord blood (UCB) can be chosen as alternative donors for allogeneic stem cell transplantation but might be associated with long lasting immune deficiency. Sixty-six patients who underwent a first transplantation from either UCB or 9/10 MMUD (n= 36) and who survived beyond 3 months were evaluated. Immune reconstitution was prospectively assessed at sequential time points after transplantation. NK, B, CD4+ and CD8+T cells and their subsets as well as regulatory T cells (Treg) were studied. Detailed analyses on infections occurring after 3 months were also assessed. The 18-month cumulative incidences of infection-related death were 8 and 3%, and of infections were 72 and 57% after MMUD and UCB transplantation, respectively. Rates of infection per 12 patient-month were roughly 2 overall (1 for bacterial, 0.9 for viral and 0.3 for fungal infections). Memory, naïve CD4+ and CD8+T cells, naïve B cells and Treg cells reconstitution between the 2 sources was roughly similar. Absolute CD4+T cells hardly reached 500 per μL by one year posttransplantation and most B cells were of naïve phenotype. Correlations between immune reconstitution and infection were then performed by multivariate analyses. Low CD4+ and high CD8+T cells absolute counts at 3 months were linked to increased risks of overall and viral (but not bacterial) infections. When assessing for the naïve/memory phenotypes at 3 months among the CD4+ T cell compartment, higher percentages of memory subsets were protective against late infections: central memory CD4+T cells protected against overall and bacterial infections; late effector memory CD4+T cells protected against overall, bacterial and viral infections. At the opposite, high percentage of effector- and late effector-memory subsets at 3 months among the CD8+ T cell compartment predicted higher risks for viral infections. Patients transplanted from alternative donors represent a population with very high risk of infection. Detailed phenotypic analysis of immune reconstitution may help to evaluate infection risk and to adjust infection prophylaxis. [less ▲]

Detailed reference viewed: 23 (6 ULg)
Full Text
Peer Reviewed
See detailAllogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas
de Masson, Adele; Beylot-Barry, Marie; Bouaziz, Jean-David et al

in Haematologica (2014), 99(3), 527-534

Detailed reference viewed: 31 (3 ULg)
Full Text
Peer Reviewed
See detailAllogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas
de Masson, Adele; Beylot-Barry, Marie; Bouaziz, Jean-David et al

in Haematologica (2014), 99(3), 527-534

Detailed reference viewed: 31 (3 ULg)
Full Text
Peer Reviewed
See detailAllogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas
de Masson, Adele; Beylot-Barry, Marie; Bouaziz, Jean-David et al

in Haematologica (2014), 99(3), 527-534

Detailed reference viewed: 31 (3 ULg)
Full Text
Peer Reviewed
See detailAllogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas
de Masson, Adele; Beylot-Barry, Marie; Bouaziz, Jean-David et al

in Haematologica (2014), 99(3), 527-534

Detailed reference viewed: 31 (3 ULg)
Full Text
Peer Reviewed
See detailPre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors
SERVAIS, Sophie ULg; Porcher, Raphael; Xhaard, Aliénor et al

in Haematologica (2014), 99(3), 519-526

Mobilized peripheral blood has become the predominant stem cell source for allogeneic hematopoietic cell transplantation. Few studies have compared outcome of HLA-matched related and HLA-matched unrelated ... [more ▼]

Mobilized peripheral blood has become the predominant stem cell source for allogeneic hematopoietic cell transplantation. Few studies have compared outcome of HLA-matched related and HLA-matched unrelated donor peripheral blood stem cell transplants. We conducted a retrospectivesingle-center analysis of 442 patients with hematologic malignancies who underwent peripheral blood stem cell transplantationfrom matched related or matched unrelated donorand we analyzed prognostic factors for long-term survival.To account for disease/status heterogeneity, patients were risk-stratified according to theDisease Risk Index.Five-year overall survival was similar aftertransplants with matched related and unrelated donor. Because donor age ≥60 years impacted outcome during model building, we further considered 3 groups of donors: matched unrelated donor (aged < 60 years by definition), matched related donor aged <60 yearsand matched related donoraged ≥60 years. In multivariate analysis, donor type/age groupand graft CD34+ and CD3+ cell doses significantly impactedlong-term survival. Transplants with matched unrelated donor and matched related donor<60years resulted in similar long-term survival while transplant with matched related donor≥60years was associated with higher risks for late mortality and treatment failure. Lower mortality risks were observed after transplant with CD34+ cell dose > 4.5 x 106/kgand CD3+ cell dose > 3 x 108/kg. The Disease Risk Index failed to predictsurvival. We builtan “Adapted Disease Risk Index” by modifying risks for myeloproliferative neoplasms and multiple myeloma, thatimproved stratification ability for progression-free survivalbut not for overall survival. [less ▲]

Detailed reference viewed: 33 (5 ULg)
Full Text
Peer Reviewed
See detailThinking out of the box - New approaches to controlling GVHD
Baron, Frédéric ULg; Humblet-Baron, Stéphanie; Ehx, Grégory ULg et al

in Current Hematologic Malignancy Reports (2014), 9

Graft-versus-host disease (GVHD) remains a major limitation of allogeneic hematopoietic cell transplantation (allo-HCT). Despite major advances in the understanding of GVHD pathogenesis, standard GVHD ... [more ▼]

Graft-versus-host disease (GVHD) remains a major limitation of allogeneic hematopoietic cell transplantation (allo-HCT). Despite major advances in the understanding of GVHD pathogenesis, standard GVHD prophylaxis regimens continue to bebased on the combination of a calcineurin inhibitor with an antimetabolite, while first line treatmentsstill relies on high-dose corticosteroids. Further, no second line treatment has emerged thus far in acute or chronic GVHD patients who failed on corticosteroids. After briefly reviewing current standards of GVHD prevention and treatment, this article will discuss recent approaches that might change GVHD prophylaxis / treatment in the next decades, with a special focus on recently developed immunoregulatory strategies based on infusion of mesenchymal stromal or regulatory T-cells, or on injection of lowdose interleukin-2. [less ▲]

Detailed reference viewed: 38 (14 ULg)
Full Text
Peer Reviewed
See detailImmune Reconstitution After Alternative Hematopoietic Stem Cell Transplantation: Comparison of Unrelated Cord Blood and Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation
Servais, Sophie ULg; Lenglinne, Etienne; Porcher, Raphael et al

in Bone Marrow Transplantation (2013, April 08), 48(S2), 132

Detailed reference viewed: 19 (3 ULg)
Full Text
Peer Reviewed
See detailDarbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation : A prospective multicenter randomized trial
BEGUIN, Yves ULg; Maertens, Johan; DE PRIJCK, Bernard ULg et al

in American Journal of Hematology (2013), 88

We conducted a randomized study analyzing the impact of darbepoetin alfa (DA) administration with or without intravenous (i.v.) iron on erythroid recovery after autologous hematopoietic cell ... [more ▼]

We conducted a randomized study analyzing the impact of darbepoetin alfa (DA) administration with or without intravenous (i.v.) iron on erythroid recovery after autologous hematopoietic cell transplantation (HCT). Patients were randomized between no DA (Arm 1), DA 300 lg every 2 weeks starting on Day 28 after HCT (Arm 2), or DA plus i.v. iron 200 mg on Days 28, 42, and 56 (Arm 3). The proportion achieving complete hemoglobin (Hb) response within 18 weeks (primary end point) was 21% in Arm 1 (n524), 79% in Arm 2 (n525), and 100% in Arm 3 (n523; P < 0.0001). Erythropoietic response was shown to be significantly higher in Arm 3 (n546) than in Arm 2 (n550; P50.008), resulting in lower DA use, reduced drug costs, and improved quality of life scores, but the effect on transfusions was not significant. In multivariate analysis, DA administration (P< 0.0001), i.v. iron administration (P50.0010), high baseline Hb (P< 0.0001), and low baseline creatinine (P50.0458) were independently associated with faster achievement of complete Hb response. In conclusion, DA is highly effective to ensure full erythroid reconstitution after autologous HCT when started on Day 28 post-transplant. I.v. iron sucrose further improves erythroid recovery. [less ▲]

Detailed reference viewed: 20 (1 ULg)
Full Text
Peer Reviewed
See detailEmerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation
SERVAIS, Sophie ULg; Beguin, Yves ULg; Baron, Frédéric ULg

in Expert Opinion on Emerging Drugs (2013), 18(2), 173-192

Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the treatment of choice for many patients suffering from hematological malignancies, severe hemoglobinopathies, bone marrow ... [more ▼]

Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the treatment of choice for many patients suffering from hematological malignancies, severe hemoglobinopathies, bone marrow failures or severe primary immunodeficiencies. Graft rejection/failure (GF) is a life-threatening complication following allo-HSCT that is most commonly caused by the reactivity of recipient T cells, natural killer (NK) cells or antibodies against donor grafted hematopoietic cells. The increasing use of allo-HSCT following reduced-intensity conditioning (RIC) and the increasing use of alternative donors (unrelated cord blood and human leukocyte antigen (HLA)-mismatched donor) have resulted in higher frequency of GF. Areas covered: This review describes the pathogenesis and current prevention and treatment of GF as well as agents in development for GF prevention or treatment. Expert opinion: The risk of GF may be reduced in the future by optimizing the conditioning regimens and post-grafting immunosuppression, increasing the number of hematopoietic stem cells (HSCs) and/or immune cells transplanted, optimizing HSC homing and better detecting patients at high risk of GF by searching for pre-transplant donor-specific anti-HLA antibodies in patients given grafts from HLA-mismatched donors, or by closely monitoring donor T- and/or NK-cell chimerism after allo-HSCT following RIC. [less ▲]

Detailed reference viewed: 23 (4 ULg)
Full Text
Peer Reviewed
See detailAllogreffe de cellules souches hématopoïétiques chez le patient âgé : jusqu'à quel âge ?
SERVAIS, Sophie ULg; WILLEMS, Evelyne ULg; Beguin, Yves ULg et al

in Revue Médicale de Liège (2013), 68(1), 38-43

In the last decades, the upper age limit for allogeneic hematopoietic cell transplantation has increased from 50-60 years to 70-75 years of age, in part due to the development of allogeneic ... [more ▼]

In the last decades, the upper age limit for allogeneic hematopoietic cell transplantation has increased from 50-60 years to 70-75 years of age, in part due to the development of allogeneic transplantation following reducedintensity or truly nonmyeloablative conditioning. This review describes challenges and opportunities of allogeneic hematopoietic cell transplantation in the elderly. [less ▲]

Detailed reference viewed: 53 (7 ULg)
Full Text
Peer Reviewed
See detailSpontaneous pneumomediastinum caused by bleomycin-induced pneumonitis
FRUSCH, Nicolas ULg; SERVAIS, Sophie ULg; DE PRIJCK, Bernard ULg et al

in Acta Clinica Belgica (2012)

We report the case of a 24-yr-old woman treated for lymphoma who developed bleomycin-induced intersitial pneumonia. This interstitial pneumonia was complicated by spontaneous pneumomediastinum ... [more ▼]

We report the case of a 24-yr-old woman treated for lymphoma who developed bleomycin-induced intersitial pneumonia. This interstitial pneumonia was complicated by spontaneous pneumomediastinum. Pneumomediastinum is an unfrequent side effect of high dose bleomycin-induced pneumonitis (BIP) and we describe the first case occurring with low-dose of bleomycin. [less ▲]

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailComment j'explore... une fièvre d'origine indéterminée chez le patient adulte ?
VERTENOEIL, Gaëlle ULg; SERVAIS, Sophie ULg; Beguin, Yves ULg

in Revue Médicale de Liège (2012), 67(7-8), 391-397

Fever of unknown origin (FUO), with more than 200 potential causes, can represent a real diagnostic challenge.For the work-up of FUO, the first step is to pay attention to each element revealed by a ... [more ▼]

Fever of unknown origin (FUO), with more than 200 potential causes, can represent a real diagnostic challenge.For the work-up of FUO, the first step is to pay attention to each element revealed by a detailed history, a complete physical examination and by some basic diagnostic tests. These elements may constitute some clues that can guide the physician for the prescription of further appropriate diagnostic examinations and procedures. If there is no real specific clues,a pet-scan seems to be useful for the work-up of FUO. [less ▲]

Detailed reference viewed: 75 (8 ULg)
Full Text
Peer Reviewed
See detailAllogreffe de cellules souches hématopoïétiques après conditionnements réduits ("minigreffes") comme traitement de certaines pathologies hématologiques malignes
SERVAIS, Sophie ULg; Baron, Frédéric ULg

in Onco Hemato (2012), 6

L’allogreffe de cellules souches hématopoïétiques est un trai¬tement efficace, proposé pour la prise en charge d’un grand nombre de pathologies hématologiques malignes. Le concept des allogreffes de ... [more ▼]

L’allogreffe de cellules souches hématopoïétiques est un trai¬tement efficace, proposé pour la prise en charge d’un grand nombre de pathologies hématologiques malignes. Le concept des allogreffes de cellules souches hématopoïétiques après un conditionnement réduit (appelées «minigreffes») repose sur deux principes essentiels: une toxicité moindre du condi¬tionnement limitant la morbidité et la mortalité reliées à la greffe et l’immunothérapie antitumorale (effet «greffe-ver¬sus-tumeur») comme mécanisme principal de l’éradication des cellules malignes. Les minigreffes ont démontré des résul¬tats encourageants dans de nombreuses pathologies héma¬tologiques malignes. Elles permettent aux patients inéligibles pour une greffe de cellules souches conventionnelle avec un conditionnement myéloablatif de bénéficier de l’effet (poten¬tiellement curatif) de la greffe contre la tumeur. Au travers de cet article, nous proposons une revue de la littérature concernant les fondements conceptuels des minigreffes de cellules souches hématopoïétiques, les particularités de ce type de greffes, les effets secondaires possibles, les résultats obtenus dans plusieurs pathologies hématologiques malignes ainsi que les indications actuellement reconnues. [less ▲]

Detailed reference viewed: 66 (5 ULg)